Background:Mirikizumab Eli Lilly and Company, Risankizumab Boehringer Ingelheim and AbbVie, Tildrakizumab Sun Pharma, Brazikumab AstraZeneca, and Guselkumab Janssen Biotech Inc. are other drugs which target IL-23 and received the FDA approval for the treatment of psoriasis.